The funds are part of the government’s $5 billion Project NextGen initiative to enable the rapid development of longer-lasting COVID-19 vaccines, a new antibody therapy and technologies to advance vaccine manufacturing processes, HHS said Tuesday.
ICON Government and Public Health Solutions, Pharm-Olam, Technical Resources Intl and Rho Federal Systems will collectively receive $1 billion to conduct clinical trials for new vaccines in partnership with the Biomedical Advanced Research and Development Authority.
Regeneron Pharmaceuticals will secure $326 million to create a next-generation monoclonal antibody therapy for COVID-19 prevention.
HHS will allocate $100 million to Global Health Investment Corp, a non-profit organization that invests in new technologies to accelerate responses to diseases and $10 million to Johnson & Johnson Innovation.
The Space Development Agency has awarded $3.5 billion in other transaction authority agreements to Lockheed Martin, L3Harris Technologies, Northrop Grumman…
The Defense Health Agency has awarded TriWest Healthcare Alliance $6.8 billion to continue providing healthcare and administrative services in support…
